Chittorgarh.com Logo
Loading...

Syngene International Ltd IPO (Syngene International IPO) Detail

Jul 27, 2015 - Jul 29, 2015

Incorporated in 1993, Syngene International Ltd is a subsidiary of Biocon Limited ("Biocon"), a global biopharmaceutical enterprise focused on delivering affordable formulations and compounds.

Headquartered in Bengaluru, Syngene International is India-based contract research organisations ("CRO"), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities ("NMEs") across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. Their services in discovery and development cover multiple domains across small molecules, large molecules, antibody-drug conjugates ("ADC") and oligonucleotides.

Syngene offer customized models as per their clients requirements. These range from a full-time equivalent ("FTE") to a fee-for-service ("FFS") model, or a combination thereof. Till Dec 31, 2014, they serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014. Company's long term clients includes global healthcare organisations Bristol-Myers Squibb Co. ("BMS"), Abbott Laboratories (Singapore) Pte. Ltd. ("Abbott") and Baxter International Inc. ("Baxter").

Company Promoters:

Biocon Limited is the promoter of the company.

Company Financials:

ParticularsFor the year/period ended (in Rs. Million)
31 Dec 1431 Mar 1431 Mar 1331 Mar 12
Total Income6,1757,0775,5424,182
Profit After Tax (PAT)1,1941,3481,021710

Objects of the Issue:

The objects of the offer are to:

1. Achieve the benefits of listing the Equity Shares on the Stock Exchanges;
2. Enhance visibility and brand image among existing and potential clients; and
3. Provide liquidity to the existing shareholders.

Syngene International IPO Details

IPO Opening Date Jul 27, 2015
IPO Closing Date Jul 29, 2015
Issue Type Book Built Issue IPO
Face Value ₹10 per equity share
IPO Price ₹240 to ₹250 per equity share
Market Lot 60 Shares
Min Order Quantity 60 Shares
Listing At BSE, NSE
Issue Size22,000,000 Eq Shares of ₹10
(aggregating up to ₹550.00 Cr)

Syngene International IPO Lot Size

The Syngene International IPO market lot size is 60 shares. A retail-individual investor can apply for up to 13 lots (780 shares or ₹195,000).

Application Lots Shares Amount (Cut-off)
Minimum 1 60 ₹15,000
Maximum 13 780 ₹195,000

Syngene International IPO Subscription Status (Bidding Detail)

The Syngene International IPO is subscribed 32.05x times on Jul 29, 2015 18:10. The public issue subscribed 4.78x in the retail category, 51.47x in the QIB category, and 90.24x in the NII category. Check Day by Day Subscription Details (Live Status)

CategoryIPO Subscription
QIB

51.47x

NII

90.24x

RII

4.78x

Others

1.37x

Total

32.05x

Syngene International IPO Prospectus

Syngene International IPO Rating

530
4.0
Rating:Rated 4.0 stars
Vote Here ...

Syngene International IPO Listing Date

Listing Date Tuesday, August 11, 2015
BSE Script Code 539268
NSE Symbol SYNGENE
Listing In B Group of Securities
ISIN INE398R01022
IPO Price ₹250 per equity share
Face Value ₹10 per equity share

Listing Day Trading Information

.
IPO Price
Open
Low
High
Last Trade
BSE
₹250.00
₹295.00
₹295.00
₹318.20
₹310.40
NSE
₹250.00
₹295.00
₹295.00
₹318.50
₹310.55

Company Contact Information

Syngene International Ltd
Biocon SEZ Biocon Park,
Plot No 2 & 3 Bommasandra Inds,
Bengaluru - 560099, Karnataka
Phone: +91-80-28082808
Email: investor@syngeneintl.com
Website: http://www.syngeneintl.com

Syngene International IPO Registrar

KFintech Private Limited

Phone: 04067162222, 04079611000
Email: einward.ris@karvy.com
Website: https://karisma.kfintech.com/

Syngene International IPO Reviews / Ratings

  • Ajcon Global Services Ltd - Apply
  • Anand Rathi - May apply
  • Angel Broking - Avoid
  • Dilip Davda - Apply
  • Hem Securities - Apply
  • KR Choksey Securities Ltd - May apply
  • Mehta Equities - Apply
  • Nirmal Bang - Apply
  • SPA Financial Advisor Ltd - Apply
  • Way2Wealth Securities - Apply

Syngene International IPO FAQs

Syngene International IPO is a main-board IPO of 22,000,000 equity shares of the face value of ₹10 aggregating up to ₹550.00 Crores. The issue is priced at ₹240 to ₹250 per equity share. The minimum order quantity is 60 Shares.

The IPO opens on Jul 27, 2015, and closes on Jul 29, 2015.

KFintech Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

The Syngene International IPO opens on Jul 27, 2015 and closes on Jul 29, 2015.

Syngene International IPO lot size is 60 Shares and the minimum order quantity is 60 Shares.

You can apply in Syngene International IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank and SBI Bank.

The finalization of Basis of Allotment for Syngene International IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Syngene International IPO allotment status.

The Syngene International IPO listing date is on Tuesday, August 11, 2015.

Syngene International IPO Message Board

Ranked Members  Ranked Members

Loading...
296. GIRISH KULKARNI |Sep 24, 2015 13:44
Forget trading. Call me for multibagger stocks. Two research reports monthly. I have a scrip which will be 10 bagger in my portfolio. Contact on gsk1595@rediffmail.com or 9765889870.
295. CHIRAG |Aug 19, 2015 14:10
Dear, I have applied for 5 Lots but not allotted any shares & not still received refund of same, can you tel me were to complaints any contact no. / mail Id
295.1. gundu anna |Aug 25, 2015 07:42
IPO Mentor IPO Mentor (500+ Posts, 100+ Likes)
If you have not been allotted, don''t worry.. you will get below IPO price over a period of time.. contract research business will always have up and down... Not a great stock for long term.. Discl: don''t hold
294. peegee |Aug 18, 2015 10:14
At what price to sell syngene int. ??
293. BABULAL KATARIA |Aug 14, 2015 20:04
THE RETAIL PORTION OF THE IPO WAS OVERSUBSCRIBED TO ONLY 4.7 TIME, BUT THE COMPANY HAS NOT ALLOTTED SHARES TO THOSE INVESTORS WHO APPLY MORE THAN 6 TIME OF THE MINIMUM LOT OF SHARES I.E. 60 SHARE. I HAVE APPLY FOR 360 SHARES BUT NOT ALLOTTED ANY SHARE. WAS INFORMED BY THE KARVY OFFICE THAT RETAIL INVESTORS WERE ALLOTTED SHARES IN THE RATIO OF 16:43 AND THAT IS THE REASON FOR NOT ALLOTMENT. NOW I OBSERVED THAT THE COMPANIES ALLOTTED ONLY ONE LOT OF SHARES TO RETAIL INVESTORS IN CASE OF OVER SUBSCRIPTION.THEREFORE, NOW EVERY RETAIL INVESTOR SHOULD APPLY FOR ONLY ONE LOT OF SHARES AND DO NOT INVEST UPTO RS. 2,00,000/-.
293.1. star ipo |Aug 14, 2015 20:10
Agreed..if all application comes with only 1 lot then confirmed aallotment to every one sure.....
292. Prakash Barnwal |Aug 13, 2015 19:20
I had applied for 780 shares of Syngene International Ltd through ICICIDIRECT.COM through at cut off price. Although the allotment is made on proportionate basis, I have not been allotted any shares. What could be the reason for this and what is the remedy left for me.
292.1. BABULAL KATARIA |Aug 14, 2015 20:16
NEXT TIME APPLY FOR ONLY ONE LOT.
291. jimb |Aug 13, 2015 10:21
Pinkyji, the basis of allotment link on this website says allotment document for syngene not released yet. I''llb grateful if u can give me the exact basis of allotmentfor each category in syngene ipo. My email is jimishb at the rate gmail dot com
291.1. pinkyjain |Aug 13, 2015 17:52
Atleast thanks me
291.2. jimb |Aug 14, 2015 13:14
Thank u pinkyji..i have yet to receive complete allotment details for biocon shareholders category...
290. jimb |Aug 12, 2015 18:27
Basis of IPO stock allocation is published by the registrar of the issue in two weeks of IPO share bid closing date.
Why is it not out for syngene yet?
290.1. star ipo |Aug 12, 2015 22:40
That''s why corrupt registrars again banned for ipo
290.2. pinkyjain |Aug 12, 2015 23:39
They are out way back what non sense

Plz provide me with your email id
289. bangalore king |Aug 12, 2015 15:45
Top Contributor Top Contributor (400+ Posts)
Here are 10 quick facts about the company.

1. Syngene International started operations in 1993 providing contract research in chemistry and biology. It now has discovery and development service offerings across small and large molecules, DNA molecules and antibody-drug conjugates.

2. Kiran Mazumdar-Shaw is the founder of Syngene. The company was first established as a private limited company in 1993 and became a public limited entity in 2007. In 2002, 99.9% of its equity shares were transferred to Biocon Ltd, making it a subsidiary of the company.

3. Silver Leaf Oak Advisors has held a 10% stake in the company since 2014.

4. Bristol Myers Squibb, Abbott Laboratories (Singapore) Pte. Ltd and Baxter International Inc. are three of its major clients. It also has smaller clients such as Achillion Pharmaceuticals Inc., Aquinox Pharmaceuticals Inc. and Saniona AB. The total count of clients as of March this year was 221, only 5% of whom are based in India.

5. Seventy percent of its revenue comes from the top 10 clients. Bristol Myers Squibb alone contributes 30%. These clients have long-term contracts.

6. It has 400 scientists working exclusively for Bristol Myers Squibb. It also has 150 scientists for Baxter and 30 scientists for Abbott.

7. Syngene has 900,000 sq. ft of work space in Bengaluru and is also in the process of setting up a 200,000 sq. ft research centre and a manufacturing facility.

8. The contract research provider has 2,685 employees, of whom 2,122 are scientists, with an average age of less than 28 years. 24% of revenue, or Rs.200 crore, went toward employee benefits in the year ended March.

9. Syngene has so far developed monoclonal antibodies, glycoproteins, complex proteins, conjugated proteins in E. coli and Chinese hamster ovary cells.

10. Clinigene is the clinical trials subsidiary of Syngene, which accounts for less than 10% of its revenue.
288. Kumaripo |Aug 12, 2015 10:28
Those who want to enter syngene may enter around 250(likely to hit within a month or two)
287. M S |Aug 11, 2015 20:39
Refund not Credited In Bank A/c.
286. Chem cho |Aug 11, 2015 17:52
IPO Guru IPO Guru (2200+ Posts, 2200+ Likes)
maximum run will not be more that RS 325

it canot go above bicom shares
285. DCC |Aug 11, 2015 17:44
Hold or sold

What so ever

Happy Listing
284. Khushaal Bhandari |Aug 11, 2015 14:04
Lot of Pent-up demand & buying seen.
Retail & HNI allotment supply was soaked up easily during 10- 11 am.
283. manu |Aug 11, 2015 13:27
Sold share @315/ all 60 shares
282. Darsh |Aug 11, 2015 12:03
IT WILL GIVE GOOD RETURN IN LONG TERM, WHEN WE ARE COMPARING IT WITH "SPARC" A SUN PHARMA SUBSIDIARY (LOSS MAKING), IT IS WORTH TO HOLD UP TO Rs. 400......
281. Anil Rajani |Aug 11, 2015 11:54
I had applied for 1 lot in the morning on the very first day. But not alloted. What is the reason???
On what basis they allot? Does the number of lots matter???

Please guide as I do not want to miss on upcoming Alkem IPO.
281.2. Anil Rajani |Aug 11, 2015 14:18
Does applying for more number of lots help?
281.3. SHASHANK K S |Aug 11, 2015 14:49
No..
But you can increase the chances of allocation by applying in the name of your family members
280. IPOANALYSIS |Aug 11, 2015 11:20
IPO Guru IPO Guru (1900+ Posts, 1500+ Likes)
SOON A PHARMA FUND WILL BUY IT. NOONE CAN GET BETTER PHARMA COMOPANY THAN THIS ONE WITH THE GROWTH POTENTIAL.

THIS STOCK IS A GEM. LOOK AT WHAT HAPPENED TO THIS WHO SOL VRL LOGISTICS AT 300 ON LISTING DAY AND ITS NOW AT 400.

SAME FATE WITH THIS GREAT COMPANY WITH PROFITS OF 175 CRORE.

EVEN THOUGH I WAS ALLOTTED IN IPO I WILL BUY MORE NOW AND KEEP ADDING THIS GROWTH STORY
280.1. gundu anna |Aug 11, 2015 21:38
IPO Mentor IPO Mentor (500+ Posts, 100+ Likes)
This is not a real pharma stock, but only contract research service provider.. do not make case for long term investment... they have waited for more than 5 years and wanted good time to sell shows it is not so good for long term investment..
279. sagrawal |Aug 11, 2015 11:17
i didn''t received my refund of syngene ipo till date.
What should i do for that
278. patel patel |Aug 11, 2015 11:15
MEMBERS HAVE NEW IPO AUGUST MAA CHE
277. Kumaripo |Aug 11, 2015 11:07
Sold all the shares @ 310
277.1. patel patel |Aug 11, 2015 11:09
GOOD LUCK
277.2. atul |Aug 11, 2015 13:26
Top Contributor Top Contributor (200+ Posts)
I bought few at 305 and few at 310